Didanosine

Excreted Unchanged %
40-69
Half-Life (Normalesrd) Hours
0.6-1.6/4.5
Plasma Protein Binding %
<5
Volume Of Distribution L/Kg
1.0
Dose For Normal Renal Function
200 mg (125 mg if <60 kg) q12h
Second Dose
Second Dose: 250-400 mg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
q12h[B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
q24h[B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% q24h[B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose after dialysis
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [B]
References
Hartman NR, Yarchoan R, Pluda JM, Thomas RV, Marczyk KS, Broder S, et al. Pharmacokinetics of 2&#146; ,3&#146; -dideoxyadenosine and 2&#146; ,3&#146; -dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther. 1990; 47: 647-54. [PMID: 2111751] / Knupp CA, Shyu WC, Dolin R, Valentine FT, McLaren C, Martin RR, et al. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther. 1991; 49: 523-35. [PMID: 1903100] / Singlas E, Taburet AM, Borsa Lebas F, Parent de Curzon O, Sobel A, Chauveau P, et al. Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis. Antimicrob Agents Chemother. 1992; 36: 1519-24. [PMID: 1510449]
Toxicity Notes
Pancreatitis.